By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MannKind Corporation 

28903 North Avenue Paine

Valencia  California  91355  U.S.A.
Phone: 661-775-5300 Fax: 661-775-2081


MannKind Corporation (Nasdaq:MNKD ) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, the Technosphere® Insulin System, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America to study its safety and efficacy in the treatment of diabetes.

MannKind is focusing on three areas:

  • First, we are continuing to execute the Technosphere® Insulin clinical trial program.
  • Second, we are moving our second potential product – a therapeutic cancer vaccine – through Phase 1 clinical trials.
  • Third, we have begun clinical testing of the next product candidate for use with our Technosphere® platform technology.

    Our values, like our work, combine the vision of our founder with the pragmatism of the laboratory. Teamwork, communication, trust and respect sum up the way we work and the way we treat our colleagues, while accountability, quality, and execution motivate the results we achieve. Finally, integrity and enthusiasm describe the spirit we bring to our jobs.

    With around six hundred employees and three locations (in California, New Jersey, and Connecticut), we have grown significantly from our founding in 1991. We continue to be a tight-knit community where each of us has a critical role in our success. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better.

    Last Updated: 04-01-2008

    Key Statistics

    Ownership: Public

    Web Site: MannKind
    Symbol: MNKD

  • Company News
    Why Struggling MannKind (MNKD) is Struggling No More 9/20/2017 5:54:51 AM
    MannKind (MNKD) Responds To Hurricane Harvey Devastation With Afrezza Donation 9/7/2017 8:57:59 AM
    Struggling MannKind (MNKD) Relocates HQ To Attract More Top Talent 9/5/2017 7:49:52 AM
    MannKind (MNKD) Reports 2017 Second Quarter Financial Results 8/8/2017 1:34:35 PM
    MannKind (MNKD) And One Drop Partner To Launch The A-One Clinical Trial 8/7/2017 10:35:08 AM
    MannKind (MNKD) To Hold 2017 Second Quarter Financial Results Conference Call On August 7, 2017 7/25/2017 11:25:39 AM
    Patrick McCauley Joins MannKind (MNKD) As Chief Commercial Officer 7/12/2017 10:40:58 AM
    Struggling MannKind (MNKD) Hires Financial Advisor After Maxing Out Its Last Credit Line 6/30/2017 6:21:00 AM
    MannKind (MNKD) Receives Accreditation From College Of American Pathologists 6/29/2017 8:11:00 AM
    MannKind (MNKD) Renegotiates Near-Term Maturities With Deerfield 6/29/2017 8:09:12 AM